WHO consultation on MERS-CoV therapeutics and vaccine evaluation

On November 30 2018, the WHO R&D Blueprint and Global Program on MERS convened a group of experts to discuss methodological issues and agree a priori on principles in the desin, conduct and analysis of Phase2b/Phase 3 clinical trials to evaluate Middle East respiratory syndrome coronavirus (MERS-CoV) therapeutics and vaccines, based on key epidemiological considerations and driven by treatment and vaccine needs from a public health perspective. The group of experts included national representatives from countries affected by MERS-CoV, experts in MERS-CoV virology and epidemiology as well as members of the R&D Blueprint working group on clinical trial design. Post-exposure

prophylaxis evaluation was not addressed within the scope of the workshop.